Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

HKD 1.16

(0.0%)

Total Debt Summary of Dawnrays Pharmaceutical (Holdings) Limited

Dawnrays Pharmaceutical (Holdings) Limited's latest annual total debt in 2023 was 120.52 Million CNY , up 1332.8% from previous year.
Dawnrays Pharmaceutical (Holdings) Limited's latest quarterly total debt in 2023 FY was 120.52 Million CNY , up 1332.8% from previous quarter.
Dawnrays Pharmaceutical (Holdings) Limited reported annual total debt of 8.41 Million CNY in 2022, down -64.23% from previous year.
Dawnrays Pharmaceutical (Holdings) Limited reported annual total debt of 23.52 Million CNY in 2021, up 697.56% from previous year.
Dawnrays Pharmaceutical (Holdings) Limited reported quarterly total debt of 120.52 Million CNY for 2023 FY, up 1332.8% from previous quarter.
Dawnrays Pharmaceutical (Holdings) Limited reported quarterly total debt of 120.52 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual Total Debt Chart of Dawnrays Pharmaceutical (Holdings) Limited (2023 - 2002)

Historical Annual Total Debt of Dawnrays Pharmaceutical (Holdings) Limited (2023 - 2002)

Year	Total Debt	Total Debt Growth
2023	120.52 Million CNY	1332.8%
2022	8.41 Million CNY	-64.23%
2021	23.52 Million CNY	697.56%
2020	2.94 Million CNY	-98.66%
2019	219.68 Million CNY	0.0%
2018	- CNY	0.0%
2017	- CNY	-100.0%
2016	9.1 Million CNY	2.9%
2015	8.84 Million CNY	-95.3%
2014	188.26 Million CNY	-24.14%
2013	248.17 Million CNY	23.01%
2012	201.75 Million CNY	82.65%
2011	110.45 Million CNY	115.92%
2010	51.15 Million CNY	397.48%
2009	10.28 Million CNY	-58.71%
2008	24.9 Million CNY	0.0%
2007	- CNY	0.0%
2006	- CNY	-100.0%
2005	17.62 Million CNY	0.0%
2004	- CNY	0.0%
2003	- CNY	0.0%
2002	- CNY	0.0%

Year	Total Debt	Total Debt Growth
2023 Q2	33.45 Million CNY	0.0%
2023 FY	120.52 Million CNY	1332.8%
2023 Q4	120.52 Million CNY	0.0%
2022 Q2	26.32 Million CNY	0.0%
2022 Q4	8.41 Million CNY	0.0%
2022 FY	8.41 Million CNY	-64.23%
2021 Q4	23.52 Million CNY	0.0%
2021 FY	23.52 Million CNY	697.56%
2021 Q2	11.77 Million CNY	0.0%
2020 Q2	116.32 Million CNY	0.0%
2020 FY	2.94 Million CNY	-98.66%
2020 Q4	2.94 Million CNY	0.0%
2019 Q4	219.68 Million CNY	0.0%
2019 Q2	200.03 Million CNY	0.0%
2019 FY	219.68 Million CNY	0.0%
2018 Q4	- CNY	0.0%
2018 Q2	80.28 Million CNY	0.0%
2018 FY	- CNY	0.0%
2017 FY	- CNY	-100.0%
2017 Q2	- CNY	0.0%
2017 Q4	- CNY	0.0%
2016 Q4	9.1 Million CNY	0.0%
2016 Q2	8.5 Million CNY	0.0%
2016 FY	9.1 Million CNY	2.9%
2015 Q4	8.84 Million CNY	0.0%
2015 FY	8.84 Million CNY	-95.3%
2015 Q2	160.4 Million CNY	0.0%
2014 Q2	233.77 Million CNY	0.0%
2014 FY	188.26 Million CNY	-24.14%
2014 Q4	188.26 Million CNY	0.0%
2013 Q2	233.6 Million CNY	0.0%
2013 FY	248.17 Million CNY	23.01%
2013 Q4	248.17 Million CNY	0.0%
2012 Q4	201.75 Million CNY	0.0%
2012 FY	201.75 Million CNY	82.65%
2012 Q2	196.17 Million CNY	0.0%
2011 Q2	141.83 Million CNY	0.0%
2011 FY	110.45 Million CNY	115.92%
2011 Q4	110.45 Million CNY	0.0%
2010 FY	51.15 Million CNY	397.48%
2010 Q2	39.25 Million CNY	0.0%
2010 Q4	51.15 Million CNY	0.0%
2009 FY	10.28 Million CNY	-58.71%
2009 Q4	10.28 Million CNY	0.0%
2009 Q2	28.1 Million CNY	0.0%
2008 FY	24.9 Million CNY	0.0%
2008 Q4	24.9 Million CNY	0.0%
2007 FY	- CNY	0.0%
2006 FY	- CNY	-100.0%
2005 FY	17.62 Million CNY	0.0%
2004 FY	- CNY	0.0%
2003 FY	- CNY	0.0%
2002 FY	- CNY	0.0%

Peer Total Debt Comparison of Dawnrays Pharmaceutical (Holdings) Limited

Name	Total Debt	Total Debt Difference
Pak Fah Yeow International Limited	6.8 Million HKD	-1669.853%
Grand Pharmaceutical Group Limited	3.4 Billion HKD	96.46%
Extrawell Pharmaceutical Holdings Limited	120.41 Million HKD	-0.097%
Wai Yuen Tong Medicine Holdings Limited	460.94 Million HKD	73.852%
Qianhai Health Holdings Limited	487 Thousand HKD	-24648.871%
Lee's Pharmaceutical Holdings Limited	204.14 Million HKD	40.959%
Essex Bio-Technology Limited	294.02 Million HKD	59.008%
Tongfang Kontafarma Holdings Limited	333.82 Million HKD	63.895%
PuraPharm Corporation Limited	424.77 Million HKD	71.625%
SSY Group Limited	3.37 Billion HKD	96.428%
JBM (Healthcare) Limited	133.4 Million HKD	9.655%
Jacobson Pharma Corporation Limited	749.37 Million HKD	83.916%
China Resources Pharmaceutical Group Limited	85.84 Billion HKD	99.86%